A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
Solid Tumor
Unknown Primary
18 Years and older, Male and Female
GO43860 (primary)
NCI-2022-08852
2021-006708-34
Summary
This is a first-in-human study to evaluate the safety, tolerability, pharmacokinetics
(PK), and anti-tumor activity of RO7502175 when administered as a single agent and in
combination with atezolizumab or pembrolizumab in adult participants with locally
advanced or metastatic solid tumors, including non-small-cell lung cancer (NSCLC), head
and neck squamous cell carcinoma (HNSCC), melanoma, triple-negative breast cancer (TNBC),
esophageal cancer, gastric cancer, cervical cancer, colorectal cancer (CRC), urothelial
carcinoma (UC), clear cell renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC).
Participants will be enrolled in 2 stages: dose escalation and dose expansion.
Eligibility
- Life expectancy at least 12 weeks
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Measurable disease according to Response Evaluation criteria in Solid Tumors (RECIST) Version 1.1
- Histologically confirmed locally advanced, recurrent, or metastatic incurable solid tumor malignancy
- Tumor Specimen availability
Treatment Sites in Georgia
**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts...
Click here to learn more about clinical trials.